« Back to Record
Citation APA

Selleslag, D., Vignetti, M., Marie, J. P., Wittnebel, S., De Witte, T., Amadori, S., Willemze, R., Baron, F., Suciu, S., Meloni, G., Muus, P., Halkes, C. J. M., Venditti, A., Ramadan, S. M., Pruijt, H., & Meert, L. (2017). Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial. Haematologica, 102(2), e47-e51. doi:10.3324/haematol.2016.153130


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/247835

Selleslag, D., Vignetti, M., Marie, J. P., Wittnebel, S., De Witte, T., Amadori, S., Willemze, R., Baron, F., Suciu, S., Meloni, G., Muus, P., Halkes, C. J. M., Venditti, A., Ramadan, S. M., Pruijt, H., & Meert, L. (2017). Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: Combined phase I/II results of the EORTC/GIMEMA AML-14A trial. Haematologica, 102(2), e47-e51. doi:10.3324/haematol.2016.153130